BKM120 is an investigational drug that blocks a molecule called PI3 kinase, which appears to function abnormally in many cancers. Olaparib kills cancer cells by blocking the PARP protein, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more vulnerable to anticancer treatments. Prior research has shown that both of these drugs may have activity against high-grade ovarian cancer.
The purpose of this study is to find the optimal doses for giving both BKM120 and olaparib in combination in women with high-grade serous cancer of the ovaries, fallopian tubes, or peritoneum (abdominal cavity) that has recurred despite standard therapy.
Both BKM120 and olaparib are taken orally (by mouth).